RJA
UTMD icon

Raymond James & Associates’s Utah Medical Products UTMD Stock Holding History

Raymond James & Associates’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,996
Closed -$692K – 4215
2021
Q1 		$692K Buy
7,996
+348
+5% +$30.6K ﹤0.01% 2770
2020
Q4 		$645K Sell
7,648
-716
-9% -$61K ﹤0.01% 2639
2020
Q3 		$668K Sell
8,364
-8,392
-50% -$696K ﹤0.01% 2438
2020
Q2 		$1.49M Buy
16,756
+463
+3% +$41.6K ﹤0.01% 1904
2020
Q1 		$1.53M Sell
16,293
-942
-5% -$87.5K ﹤0.01% 1727
2019
Q4 		$1.86M Sell
17,235
-435
-2% -$44.1K ﹤0.01% 1871
2019
Q3 		$1.69M Sell
17,670
-65
-0.4% -$6.04K ﹤0.01% 1875
2019
Q2 		$1.7M Buy
17,735
+756
+4% +$63.6K ﹤0.01% 1893
2019
Q1 		$1.5M Buy
16,979
+1,542
+10% +$136K ﹤0.01% 1952
2018
Q4 		$1.28M Sell
15,437
-612
-4% -$53.9K ﹤0.01% 1938
2018
Q3 		$1.51M Buy
16,049
+5,945
+59% +$568K ﹤0.01% 1986
2018
Q2 		$1.11M Buy
10,104
+1,508
+18% +$157K ﹤0.01% 2128
2018
Q1 		$850K Buy
+8,596
New +$767K ﹤0.01% 2252

Other funds holding UTMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's UTMD Position: Q2 2021 in Review

Raymond James & Associates sold out of Utah Medical Products (UTMD) in Q2 2021, closing a stake of 7,996 shares — an estimated $692K sold.

Raymond James & Associates first reported a position in UTMD in Q1 2018 and held it in 13 quarters. The position peaked at $1.86M in Q4 2019. 68 funds tracked by Wall St. Rank hold UTMD as of Q2 2021.

  • Raymond James & Associates reported no remaining Utah Medical Products position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 7,996 Utah Medical Products shares in Q2 2021, an estimated $692K.
  • Raymond James & Associates first reported a position in Utah Medical Products in Q1 2018 and held it in 13 quarters.
  • Raymond James & Associates's Utah Medical Products position peaked at $1.86M in Q4 2019.
  • 68 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.